Welcome to CDC stacks | SARS Vaccine Protective in Mice - 14732 | Emerging Infectious Diseases
Stacks Logo
Advanced Search
Select up to three search categories and corresponding keywords using the fields to the right. Refer to the Help section for more detailed instructions.
 
 
Help
Clear All Simple Search
Advanced Search
SARS Vaccine Protective in Mice
  • Published Date:
    Aug 2005
  • Source:
    Emerg Infect Dis. 11(8):1312-1314.
Filetype[PDF-53.71 KB]


No Related Documents.
You May Also Like:
  1. SARS Vaccine Development
    Personal Author:
    Jiang, Shibo; He, Yuxian; Liu, Shuwen;
    Published:
    Jul 2005
    Source:
    Emerg Infect Dis. 11(7):1016-1020.
    Description:
    Developing effective and safe vaccines is urgently needed to prevent infection by severe acute respiratory syndrome (SARS)-associated coronavirus (SARS-CoV). The inactivated SARS-CoV vaccine may be the first one available for clinical use because it ...
    File Type:
    Filetype[PDF - 95.26 KB]
  2. Emerging Infectious Diseases: a 10-Year Perspective from the National Institute of Allergy and Infectious Diseases
    Personal Author:
    Fauci, Anthony S.; Touchette, Nancy A.; Folkers, Gregory K.;
    Published:
    Apr 2005
    Source:
    Emerg Infect Dis. 11(4):519-525.
    Description:
    Although optimists once imagined that serious infectious disease threats would by now be conquered, newly emerging (e.g., severe acute respiratory syndrome [SARS]), reemerging (e.g., West Nile virus), and even deliberately disseminated infectious dis...
    File Type:
    Filetype[PDF - 228.68 KB]
  3. Toward Developing a Preventive MERS-CoV Vaccine—Report from a Workshop Organized by the Saudi Arabia Ministry of Health and the International Vaccine Institute, Riyadh, Saudi Arabia, November 14–15, 2015
    Personal Author:
    Excler, Jean-Louis; Delvecchio, Christopher J.; Wiley, Ryan E.; Williams, Marni; Yoon, In-Kyu; Modjarrad, Kayvon; Boujelal, Mohamed; Moorthy, Vasee S.; Hersi, Ahmad Salah; Kim, Jerome H.;
    Corporate Author:
    on behalf of the MERS-CoV Vaccine Working Group
    Published:
    Aug 2016
    Source:
    Emerg Infect Dis. 22(8).
    Description:
    Middle East respiratory syndrome (MERS) remains a serious international public health threat. With the goal of accelerating the development of countermeasures against MERS coronavirus (MERS-CoV), funding agencies, nongovernmental organizations, and r...
    File Type:
    Filetype[PDF - 823.75 KB]
  4. Longitudinally Profiling Neutralizing Antibody Response to SARS Coronavirus with Pseudotypes
    Personal Author:
    Temperton, Nigel J.; Chan, Paul K.; Simmons, Graham; Zambon, Maria C.; Tedder, Richard S.; Takeuchi, Yasuhiro; Weiss, Robin A.;
    Published:
    Mar 2005
    Source:
    Emerg Infect Dis. 11(3):411-416.
    Description:
    The severe acute respiratory syndrome-associated coronavirus (SARS-CoV) spike protein (S) is a major target for neutralizing antibodies. Retroviral SARS-CoV S pseudotypes have been constructed and used to develop an in vitro microneutralization assay...
    File Type:
    Filetype[PDF - 203.46 KB]
  5. Matrix Protein 2 Vaccination and Protection against Influenza Viruses, Including Subtype H5N1
    Personal Author:
    Tompkins, Stephen Mark; Zhao, Zi-Shan; Lo, Chia-Yun; Misplon, Julia A.; Liu, Teresa; Ye, Zhiping; Hogan, Robert J.; Wu, Zhengqi; Benton, Kimberly A.; Tumpey, Terrence M.; Epstein, Suzanne L.;
    Published:
    Mar 2007
    Source:
    Emerg Infect Dis. 13(3):426-435.
    Description:
    Changes in influenza viruses require regular reformulation of strain-specific influenza vaccines. Vaccines based on conserved antigens provide broader protection. Influenza matrix protein 2 (M2) is highly conserved across influenza A subtypes. To eva...
    File Type:
    Filetype[PDF - 430.68 KB]